Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Hisamitsu’s Osteoarthritis Patch Drug Fails in US PIII Study
Hisamitsu Pharmaceutical’s analgesic transdermal patch HP-5000 (diclofenac) failed to meet the primary goal in a US PIII study conducted for the treatment of osteoarthritis knee pain, the Japanese patch drug powerhouse said on October 28.The trial enrolled 370 patients with…
To read the full story
Related Article
- Hisamitsu’s Osteoarthritis Patch Drug Enters PIII in US
January 6, 2021
- Hisamitsu’s Osteoarthritis Patch Drug Delivers Positive PII Data; PIII Launch Planned in FY2020
November 27, 2019
- Hisamitsu Launches US PII Study for Analgesic Transdermal Patch
September 26, 2017
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…